Selected article for: "acute respiratory syndrome and live viral vaccine"
Author: Sampath Kumar, N. S.; Chintagunta, Anjani Devi; Jeevan Kumar, S. P.; Roy, Sharmili; Kumar, Mahesh
Title: Immunotherapeutics for Covid-19 and post vaccination surveillance
  • Cord-id: a6yncx3p
  • Document date: 2020_11_11
    • ID: a6yncx3p
    Snippet: Severe acute respiratory syndrome coronavirus (SARS-CoV-2) has emerged as a pandemic and named as novel coronavirus disease (nCOVID-19). SARS-CoV-2 is different from other known viruses due to multiple mutations on the sites of nonstructural proteins (NSP) 2 and 3, and the varying nature of virulence between different persons. Immunotherapies such as vaccines and monoclonal antibodies have a protective effect on the patients bringing them to the front of the line of potential treatments. The pre
    Document: Severe acute respiratory syndrome coronavirus (SARS-CoV-2) has emerged as a pandemic and named as novel coronavirus disease (nCOVID-19). SARS-CoV-2 is different from other known viruses due to multiple mutations on the sites of nonstructural proteins (NSP) 2 and 3, and the varying nature of virulence between different persons. Immunotherapies such as vaccines and monoclonal antibodies have a protective effect on the patients bringing them to the front of the line of potential treatments. The present review intends to cover the development of 20 different vaccine candidates categorized under live attenuated vaccines, inactivated vaccines, subunit vaccines, viral vector-based vaccines, and nucleic acid vaccines. Formulation of these vaccine candidates by various companies in collaboration with global organizations and their status of clinical trials were addressed. On the other hand, various approaches for post-vaccination surveillance using nucleic acid and protein biomarkers imbued on suitable platforms were also highlighted to sum up the immune therapeutics for Covid-19.

    Search related documents:
    Co phrase search for related documents
    • active surveillance activity and acute respiratory syndrome: 1
    • active surveillance and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active surveillance and adenoviral vector: 1
    • acute respiratory syndrome and ade antibody dependent enhancement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adenoviral vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and adjuvant immunogenicity increase: 1
    • acute respiratory syndrome and adjuvant system: 1, 2
    • ade antibody dependent enhancement and adjuvant system: 1, 2, 3
    • adenoviral vector and adjuvant system: 1